Europe · Regional markets · Het Financieele Dagblad

Met zijn Wegovy-pil haalt Novo concurrent Eli Lilly nog niet in

Published by Het Financieele Dagblad · Netherlands 11 h ago

Novo presteerde in het derde kwartaal beter dan verwacht, mede dankzij het succes van zijn Wegovy-pil. De vraag is of het genoeg is om concurrent Eli Lilly bij te houden.

Read the full article on Het Financieele Dagblad Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (fd.nl)

Also worth reading

This is Money

One of Britain's top female executives to scoop millions as new boss of US tech giant

City A.M.

OBR warns Healey: Stealth taxes to blame for living standards slump

Investors Chronicle

US election results send shares higher

Finews

Private bank appoints branch manager, client advisor and South Africa specialist

MoneyWeek

China is a technology powerhouse: how can you gain exposure?

Maddyness